Related Experiment Video
Updated: Mar 3, 2026
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group
Alexis Ogdie1,2, Maarten de Wit3,4, Kristina Callis Duffin3,4
1From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey. alexis.ogdie@uphs.upenn.edu.
The updated 2016 psoriatic arthritis (PsA) core domain set, developed by GRAPPA-OMERACT, defines key features for clinical trials. This work guides the creation of a comprehensive PsA core outcome measurement set.
Area of Science:
- Rheumatology
- Clinical Trial Methodology
Background:
- The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) PsA Core Set working group identified essential disease features for clinical trials.
- An updated 2016 psoriatic arthritis (PsA) core domain set was recently published.
Purpose of the Study:
- To review the development process of the PsA core domain set.
- To outline ongoing and proposed work streams for developing a PsA core outcome measurement set.
Main Methods:
- Review of the development process for the PsA core domain set.
- Presentation of findings at the GRAPPA annual meeting (July 2016) and OMERACT (May 2016).
Main Results:
- The updated 2016 PsA core domain set was endorsed by 90% of OMERACT participants.
- A roadmap for the development of the PsA core outcome measurement set was drafted.
Conclusions:
- The PsA core domain set is established and guides future outcome measure development.
- Ongoing work focuses on creating a comprehensive measurement set for psoriatic arthritis clinical trials.
More Related Videos
Related Concept Videos
01:11Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
01:11Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...